PhylloTech, LLC (Madison, WI) announces that it has been awarded a $200,000 RAPID Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). The company will use their plant bioproduction platform to generate and secrete antibodies in a manner that avoids extraction and purification costs. “We are excited to apply our technology to the therapeutic antibody market,” said Danielle Wittenwyler, Ph.D., R&D Manager at PhylloTech. “Our platform could redefine antibody production with sustainable manufacturing practices and minimized costs.”
“Antibodies are used as everyday research tools and to diagnose and treat a spectrum of diseases that includes cancer, lethal viruses, and asthma,” said Ryan Shepherd, Ph.D., PhylloTech’s Chief Executive Officer. “Antibody production is an excellent application of our technology and we could have an enormous impact on the treatment of current and emerging diseases.” PhylloTech is an agricultural biotechnology company that is also developing innovative strategies for plant disease control. PhylloTech is headquartered at the University Research Park in Madison, WI. Please visit www.phyllotech.com for further information.